source
- Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
- Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosisEli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…